Ribavirin News and Research

RSS
Ribavirin, also known as Copegus, Rebetol, Virazole, or a component of Rebetron, is a type of antiviral medicine called a nucleoside analogue. This medicine blocks the ability of the hepatitis C virus (HCV) to make more copies of itself. Ribavirin is not active against HIV. Ribavirin is used in combination with interferon alfa-2a or -2b or peginterferon alfa-2a or -2b to treat HIV infected patients who are also infected with HCV.
Trial of new ‘combo’ treatment for hepatitis C

Trial of new ‘combo’ treatment for hepatitis C

HCV protease inhibitor telaprevir improves response, halves treatment time for hepatitis C patients

HCV protease inhibitor telaprevir improves response, halves treatment time for hepatitis C patients

Anti-viral ribavirin may prove effective in treatment of many cancers

Anti-viral ribavirin may prove effective in treatment of many cancers

Anti-viral drug telaprevir improves response, halves duration of hepatitis C treatment

Anti-viral drug telaprevir improves response, halves duration of hepatitis C treatment

Roche and Pharmasset start phase IIb clinical trial of R7128 nucleoside polymerase inhibitor for chronic hepatitis C

Roche and Pharmasset start phase IIb clinical trial of R7128 nucleoside polymerase inhibitor for chronic hepatitis C

Early treatment for hepatitis C offers a good chance of a cure

Early treatment for hepatitis C offers a good chance of a cure

Mutations within a conservative region of hepatitis C virus affect therapy

Mutations within a conservative region of hepatitis C virus affect therapy

Researchers investigate new way to block reproduction of the hepatitis C virus

Researchers investigate new way to block reproduction of the hepatitis C virus

Hep C treatment pegylated interferon reduces the virus but liver damage continues

Hep C treatment pegylated interferon reduces the virus but liver damage continues

Hep C treatment peginterferon reduces the virus but liver damage continues

Hep C treatment peginterferon reduces the virus but liver damage continues

Interferon as long-term treatment for hepatitis C not effective

Interferon as long-term treatment for hepatitis C not effective

Low-dose peginterferon used for hepatitis C doesn't work

Low-dose peginterferon used for hepatitis C doesn't work

Anadys Pharmaceuticals receives fast track for ANA598 treatment of chronic hepatitis C virus

Anadys Pharmaceuticals receives fast track for ANA598 treatment of chronic hepatitis C virus

Researchers develop new strategy for broad spectrum anti-viral drugs

Researchers develop new strategy for broad spectrum anti-viral drugs

Tibotec presents interim findings for TMC435, investigational hepatitis C treatment

Tibotec presents interim findings for TMC435, investigational hepatitis C treatment

GSK to acquire Genelabs Technologies

GSK to acquire Genelabs Technologies

Anti-itching drug clemizole shows promise against hepatitis C

Anti-itching drug clemizole shows promise against hepatitis C

New studies examine use of the nucleoside polymerase inhibitor, R1626, to the standard therapy for hepatitis C

New studies examine use of the nucleoside polymerase inhibitor, R1626, to the standard therapy for hepatitis C

Hepatitis C therapy peginterferon alfa-2b shows promise

Hepatitis C therapy peginterferon alfa-2b shows promise

Risk factors for severe RSV infection in immunocompromised children

Risk factors for severe RSV infection in immunocompromised children